Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Anika Therapeutics (ANIK) Accumulated Depreciation & Amortization (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Accumulated Depreciation & Amortization for 16 consecutive years, with $51.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 11.11% to $51.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $51.4 million through Dec 2025, up 11.11% year-over-year, with the annual reading at $51.4 million for FY2025, 11.11% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $51.4 million at Anika Therapeutics, up from $50.6 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $51.4 million in Q4 2025, with the low at $39.6 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $46.5 million, with a median of $46.3 million recorded in 2024.
  • The sharpest move saw Accumulated Depreciation & Amortization grew 16.67% in 2022, then decreased 4.75% in 2023.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $39.6 million in 2021, then grew by 16.67% to $46.2 million in 2022, then decreased by 4.75% to $44.0 million in 2023, then increased by 5.22% to $46.3 million in 2024, then grew by 11.11% to $51.4 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $51.4 million, $50.6 million, and $47.6 million for Q4 2025, Q2 2025, and Q1 2025 respectively.